Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sawai to Raise Awareness for Launch of Alcoholism Therapy App HAUDY
Sawai Pharmaceutical will roll out Japan’s first digital therapeutic for alcohol use disorder (AUD) on September 1, with President Motohiko Kimura vowing to use the debut to drive greater public awareness of the disease. The app, branded as CureApp AUD…
To read the full story
Related Article
- Sawai Eyes Digital and Device Business as Next Growth Pillar after Generics
December 2, 2025
- Japan Approves Reimbursement for CureApp’s Alcohol Reduction Digital Therapeutic
July 17, 2025
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Shionogi’s ADHD Game Therapy, CureApp’s Alcoholism App in Line for Approval
February 7, 2025
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
- CureApp Files Alcoholism Therapy App in Japan
March 26, 2024
BUSINESS
- Otsuka Eyes 3.5 Trillion Yen Sales by 2035 on New Growth Drivers
August 3, 2026
- Daiichi Sankyo Cuts FY2027 Net Profit Outlook on Higher Tax Burden
August 3, 2026
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…